PPCB
Propanc Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · AU
$1.01
−0.98%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | 21.7K | 17.8K | — |
| Gross Profit | — | — | (21.7K) | (17.8K) | (5.7K) |
| Operating Expenses | |||||
| R&D Expense | 303.3K | 223.7K | 248.1K | 247.9K | 256.1K |
| SG&A Expense | 18.1M | 57.1M | 1.3M | 1.5M | 1.7M |
| General & Admin Expense | 18.1M | 57.1M | 1.3M | 1.5M | 1.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 18.4M | 57.3M | 1.5M | 1.8M | 2.0M |
| Cost and Expenses | 18.4M | 57.3M | 1.5M | 1.8M | 2.0M |
| Operating Income (EBIT) | (18.4M) | (57.3M) | (1.5M) | (1.8M) | (2.0M) |
| Non-Operating | |||||
| Interest Income | 76.00 | 9.00 | 60.00 | 36.00 | 5.6K |
| Interest Expense | 657.4K | 563.8K | 665.8K | 532.8K | 568.8K |
| Net Interest Income | (657.3K) | (563.7K) | (666.0K) | (533.0K) | (563.0K) |
| Other Non-Op Income/Expense | 12.8K | (1.6M) | (414.0K) | (1.0M) | (722.0K) |
| Non-Operating Income (excl Interest) | (670.3K) | 1.1M | (252.0K) | 480.9K | 153.4K |
| EBT (Pre-Tax Income) | (18.4M) | (58.9M) | (1.9M) | (2.8M) | (2.7M) |
| Income Tax Expense | — | — | (129.0K) | (130.0K) | (55.0K) |
| Bottom Line | |||||
| Net Income | (18.4M) | (58.9M) | (1.8M) | (2.7M) | (2.7M) |
| Earnings from Cont. Ops | (18.4M) | (58.9M) | (1.8M) | (2.7M) | (2.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (19.3M) | (58.9M) | (2.0M) | (3.1M) | (3.4M) |
| Per Share | |||||
| Basic EPS | ($33.00) | ($371.25) | ($35,523.75) | ($781,709.75) | ($27,986,891.75) |
| Diluted EPS | ($33.00) | ($371.25) | ($30,000.00) | ($781,709.75) | ($27,986,891.75) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 897099 | 158727 | 57 | 4 | 0 |
| Diluted Shares Outstanding | 897099 | 158727 | 57 | 4 | 0 |
| Profitability Metrics | |||||
| EBITDA | (17.7M) | (58.3M) | (1.3M) | (2.2M) | (2.1M) |
| D&A | 21.6K | 20.2K | 21.7K | 22.9K | 2.0K |
| EBIT | (17.7M) | (58.4M) | (1.3M) | (2.3M) | (2.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026